Gene Therapy Manufacturing: Scale Up, Scale Out Or Drop Out
As academia finally delivers on the promise of gene therapy, the manufacturing challenges arrive.
You may also be interested in...
US investigators fan out to non-China inspection priorities and Secretary Azar talks supply management; warning letters hit record keeping, investigations and basic GMP compliance.
After realizing some generics don’t work, academic medical center screens quality by manufacturer. Other providers protest: It’s not our job.
Agency agrees with those who prescribe and buy drugs on need to incentivize quality. Except providers want it yesterday.